111 related articles for article (PubMed ID: 35067601)
1. Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas.
Sun L; Schroeder MC; Hagemann IS; Pfeifer JD; Schwarz JK; Grigsby PW; Markovina S; Lin AJ
Int J Gynecol Pathol; 2022 Nov; 41(6):628-635. PubMed ID: 35067601
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
5. Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J; Edelweiss M; Ross DS; Xu B; Moo TA; Brogi E; D'Alfonso TM
Arch Pathol Lab Med; 2021 Jun; 145(6):728-735. PubMed ID: 33112958
[TBL] [Abstract][Full Text] [Related]
6. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
7. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
8. Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas.
Hanken H; Gaudin R; Gröbe A; Fraederich M; Eichhorn W; Smeets R; Simon R; Sauter G; Grupp K; Izbicki JR; Sehner S; Heiland M; Blessmann M
J Oral Pathol Med; 2014 Apr; 43(4):304-8. PubMed ID: 24645976
[TBL] [Abstract][Full Text] [Related]
9. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
10. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence.
Conesa-Zamora P; Torres-Moreno D; Isaac MA; Pérez-Guillermo M
Exp Mol Pathol; 2013 Oct; 95(2):151-5. PubMed ID: 23827764
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis.
Dong SW; Wang L; Sui J; Deng XY; Chen XD; Zhang ZW; Liu X; Liu ZM; Zhang JH; Yang QS; Jia YF; Song X
Mol Diagn Ther; 2011 Aug; 15(4):211-9. PubMed ID: 21913743
[TBL] [Abstract][Full Text] [Related]
12. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification.
Shi H; Shao Y; Lu W; Lu B
J Pathol Clin Res; 2021 Jan; 7(1):86-95. PubMed ID: 33089969
[TBL] [Abstract][Full Text] [Related]
13. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
14. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
15. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani S; Ciniselli CM; Leonardi E; Polla E; Decarli N; Luchini C; Cantaloni C; Gasperetti F; Cazzolli D; Berlanda G; Bernardi D; Pellegrini M; Triolo R; Ferro A; Verderio P; Barbareschi M
Virchows Arch; 2016 Jul; 469(1):45-50. PubMed ID: 27097809
[TBL] [Abstract][Full Text] [Related]
16. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
Stewart RL; Caron JE; Gulbahce EH; Factor RE; Geiersbach KB; Downs-Kelly E
Mod Pathol; 2017 Nov; 30(11):1561-1566. PubMed ID: 28752841
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
18. HER2 Amplification Status in Feline Mammary Carcinoma: A Tissue Microarray-Fluorescence In Situ Hydridization-Based Study.
Muscatello LV; Di Oto E; Sarli G; Monti V; Foschini MP; Benazzi C; Brunetti B
Vet Pathol; 2019 Mar; 56(2):230-238. PubMed ID: 30384816
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
20. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
